Frailty Strong Predictor of Complications and Mortality in Type 1 Diabetes: Study
Finland: Researchers have found in a new study that frailty, frequently observed in people with type 1 diabetes, is an independent predictor of earlier and increased risk of complications and death. Therefore, frailty assessment could enhance risk stratification and help guide personalized care.
A new study published in Diabetes Research and Clinical Practice by Markus J. Haapanen from the University of Helsinki and colleagues highlights the critical role of frailty in shaping long-term outcomes for adults living with type 1 diabetes. While traditional risk factors such as blood pressure, glycemic control, or lipid levels are routinely used to predict complications, this research shows that frailty—a measure reflecting accumulated health deficits—may be a more powerful predictor.
The study analyzed data from 4,819 adults enrolled in the nationwide FinnDiane cohort, one of the most comprehensive long-term research databases for type 1 diabetes. Participants, aged 18 to 81 years at baseline, were categorized as non-frail, pre-frail, or frail using a validated frailty index. They were followed for a median of 19 years through national health registries, with researchers tracking major cardiovascular events, need for kidney replacement therapy, severe retinopathy, and both all-cause and cause-specific mortality.
To assess predictive performance, the researchers used advanced statistical models, including Cox, Fine–Gray, and Weibull analyses.
Key Findings:
- One-third of participants were non-frail at baseline, over half were pre-frail, and 13% were classified as frail, indicating that frailty is common even at relatively young ages in people with type 1 diabetes.
- Frail individuals faced markedly higher risks of complications, with hazards ranging from threefold to as high as 118-fold compared with non-frail participants.
- Major complications occurred two to six years earlier in frail individuals, showing accelerated disease progression.
- Frailty was linked to a tenfold higher risk of all-cause mortality, with frail participants living an average of 4.5 fewer years than non-frail individuals.
- Frailty showed strong discriminative performance and outperformed individual conventional risk factors, indicating its added prognostic value beyond standard clinical markers.
The authors emphasize that frailty is more than a marker of aging—it is a powerful, independent indicator of vulnerability in type 1 diabetes. Recognizing and measuring frailty may provide clinicians with a more complete understanding of patient health, enabling earlier interventions and more tailored management strategies.
However, the study also highlights the need for further investigation to determine how best to incorporate frailty assessments into routine practice. While frailty appears to be a robust predictor, more research is needed to confirm how it can be used to guide treatment decisions and improve long-term patient outcomes.
"With growing evidence supporting its prognostic value, frailty assessment may soon become an important tool in managing the long-term health of individuals with type 1 diabetes," the authors concluded.
Reference:
Haapanen, M. J., Sigfrids, F. J., Ylinen, A., Satuli-Autere, S., Nicklén, J., Groop, P., Harjutsalo, V., & Thorn, L. M. (2025). Frailty outperforms conventional risk factors for predicting complications and death in type 1 diabetes. Diabetes Research and Clinical Practice, 112984. https://doi.org/10.1016/j.diabres.2025.112984
Next Story